A valuation cap sets a ceiling on the price at which a convertible instrument converts into equity, protecting early investors from dilution if the company's valuation rises sharply before the next priced round. At conversion, the investor gets the better of the cap price or the discounted round price, not both. A post-money cap fixes the investor's ownership percentage, while a pre-money cap can shift with other converting instruments. Setting a cap too low can create heavy dilution and signal a low valuation to later investors.

Why it matters

In MedTech, caps are calibrated to expected milestones - caps often step up after first-in-human data, CE mark, or FDA clearance. A cap that's too low gives away too much equity; too high and early investors won't bite.

Common pitfalls

•Negotiating a cap without modeling the implied ownership percentage at conversion under various Series A scenarios.

Sources

Carta: valuation caps explained · Carta
PitchBook - MedTech Coverage · PitchBook
NVCA Model Documents · NVCA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.